Litigation Update: Zantac Developments

The Judicial Panel on Multidistrict Litigation (JPML) is expected to consider creating an MDL for the Zantac litigation at its upcoming hearing in early December. Considering that Zantac (ranitidine) has been on the market for decades and was so widely-used, the number of potential claimants is expected to be significant.

Contrary to the recent FDA announcement, there is evidence that the issue with Zantac is not contamination but is instead the actual molecular structure of the drug, which is converted in the body into N-nitrosodimethylamine (NDMA). NDMA is classified as a probable human carcinogen by the FDA, the EPA and IARC (International Agency for Research on Cancer).

A 2016 study by environmental researchers at Stanford and Syracuse University tested the urine of ten healthy subjects prior to and after ingestion of a 150mg Zantac tablet. Levels of NDMA in the urine increased over 400 times after taking the Zantac tablet.

More recently, Valisure LLC, a Connecticut-based online analytical pharmacy that routinely tests medications, also found a link between ranitidine and NDMA and filed a citizen petition with the FDA urging the FDA Commissioner to request a recall and suspend sales of ranitidine.

In a statement, David Light, CEO of Valisure, stated that their research “found that NDMA was the result of the “inherent instability” of the ranitidine molecule. This means that all manufacturers, brand or generic, and all lots of ranitidine-containing medications are affected and could generate very high levels of NDMA in the human body.”

Click on this link for information on Verus’ Mass Tort Services. To contact us, fill out this form or email us at and we will reply immediately.

See also  Appeals court hears arguments over Monsanto’s first Roundup trial loss


V.P. of Mass Torts Services, General Counsel

Deb is a lawyer with over 25 years of legal and business experience. As the leader of mass tort services at Verus, she oversees the support services provided to law firms involved in mass tort litigation, specifically in the areas of case management, claimant contact and medical record review. More

Spread the love

Author: Edward Lott

Edward Lott, Ph.D., M.B.A. is President and Managing Partner of Allentown-based ForLawFirmsOnly Marketing, Inc., a client acquisition company that offers attorneys signed client cases.Ed has been a digital entrepreneur since 1994, having discovered very early the opportunities the Internet offered. After having spent over two decades helping small business owners, Ed joined the staff of ForLawFirmsOnly Marketing as President and Managing Partner, where he is expanding the agency's cutting-edge services.A true marketing futurist, Ed's vast experience working directly with attorneys has given him a unique perspective on law firm marketing not found in many other digital marketing agencies. Ed has reshaped the offerings of ForLawFirmsOnly to focus on growing law firms through a holistic approach to digital marketing evident in the reformulated lead generation processes now in place. He is taking that same holistic approach for small businesses, helping them grow their bottom line.Want to learn more about ForLawFirmsOnly Marketing, our client acquistion services or lead generation programs, or just talk to Ed about his visions for helping your business grow? Call him at 855-943-8736.

Copyright ©2021 Medical Injury Help, ForLawFirmsOnly Marketing, Inc. All Rights Reserved